NCT06290128 · Sanofi
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
(MOBILIZE)
What this study is about
The purpose of the study is to evaluate effectiveness of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to the usual treatment. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.
View original scientific description
The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.
Interventions
DRUG
Riliprubart
Pharmaceutical form: Solution Route of administration: IV Infusion
DRUG
Placebo
Pharmaceutical form: Solution Route of administration: IV Infusion
DRUG
Riliprubart
Pharmaceutical form: Solution Route of administration: SC Injection
DRUG
Placebo
Pharmaceutical form: Solution Route of administration: SC Injection
Primary outcome measures
Percentage of participants experiencing a response
Time frame: Baseline to week 24
A response is defined as a decrease of ≥1 point from baseline in adjusted INCAT disability score at Week 24.
Percentage of participants randomized to riliprubart with lasting response
Time frame: Baseline to week 48
Lasting response is defined as a decrease of ≥1 point in adjusted INCAT disability score at week 48 versus baseline.
Percentage of participants randomized to placebo who experience a response
Time frame: Week 24 to week 48
A response is defined as a decrease of ≥1 point in adjusted INCAT disability score at Week 48 versus week 24.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Participants are eligible to be included in the study only if all of the following criteria apply: -Participant must have CIDP or possible CIDP criteria, based on European Academy of Neurology (EAN)/ Peripheral Nerve Society (PNS) Task Force CIDP guidelines, second revision (2021).
- Participant must have either typical CIDP, or one of the following two CIDP variants: motor CIDP (including motor predominant), multifocal CIDP (also known as Lewis Sumner Syndrome). Diagnosis must be confirmed by the adjudication committee.
- Participant must be refractory to either immunoglobulin therapy or corticosteroid therapy, as defined below.
- Immunoglobulinrefractory subgroup: Historic evidence of failure or inadequate response to immunoglobulin therapy prior to screening, defined as no clinically meaningful improvement or persistent INCAT score ≥2 after a minimum of:
- One dose of IVIg of 2 g/kg, followed by a second dose of 2 g/kg or two doses of 1 g/kg, with a se
Where
- Homewood, Alabama
- Los Angeles, California
- Orange, California
- Centennial, Colorado
- New Haven, Connecticut
- Bradenton, Florida
- Miami Lakes, Florida
- Glenview, Illinois
- Kansas City, Kansas
- Alexandria, Louisiana
- New Orleans, Louisiana
- Baltimore, Maryland
And 15 more locations — see the full list below.
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jun 12, 2026 · Source of record for eligibility and locations